Type 2 diabetes management has evolved rapidly in recent years with increasing emphasis on cardiovascular risk reduction, weight management and early use of therapies with proven outcome benefits. Updates to NICE NG28 reflect this shift and require clinicians to move beyond a purely glycaemic-centric approach to treatment.

This session will provide a practical overview of the latest updates to the NICE NG28 guideline and their implications for clinical practice. Key topics will include treatment selection beyond metformin, the role of SGLT2 inhibitors and GLP-1 receptor agonists, and how patient characteristics such as cardiovascular disease, weight and comorbidities influence therapeutic decisions.

Using real-world case studies, the session will demonstrate how pharmacists can apply the updated guidance to optimise treatment, support multidisciplinary decision-making and improve cardiovascular and metabolic outcomes for people with type 2 diabetes.